Just Diagnosed with Bardet-Biedl Syndrome? A Comprehensive Guide to Understanding Your Condition

Just Diagnosed with Bardet-Biedl Syndrome? A Comprehensive Guide to Understanding Your Condition

Receiving a diagnosis of Bardet-Biedl Syndrome (BBS) can bring a wave of emotions — confusion, fear, relief at finally having answers, or all of these at once. Whatever you are feeling right now is valid. This guide is written specifically for you: someone who has just learned they have BBS. It will walk you through what the condition means, what to expect, what treatments exist today, and where to find support. You are not alone — there is a dedicated community of patients, families, researchers, and clinicians working to improve life with BBS every day.

What is Bardet-Biedl Syndrome?

Bardet-Biedl Syndrome is a rare genetic condition classified as a ciliopathy — a disorder of the cilia, which are microscopic hair-like structures found on nearly every cell in your body. Cilia act as cellular antennae, helping cells sense their environment and communicate. When the genes responsible for building or maintaining cilia carry mutations, multiple organ systems can be affected.

BBS is estimated to affect approximately 1 in 100,000 to 1 in 160,000 people in North America and Europe, though prevalence is higher in certain populations including Newfoundland (Canada), Kuwait, and some Bedouin communities. More than 26 genes have been identified that can cause BBS (BBS1 through BBS22, plus additional modifier genes), with BBS1 and BBS10 being the most common.

Because cilia are present throughout the body, BBS can affect multiple systems simultaneously. However, every person with BBS is different — you may experience some features more prominently than others, and the severity varies considerably between individuals, even those with the same genetic mutation.

How BBS Affects Your Body

The primary features of BBS typically include:

Vision Changes (Retinal Dystrophy): Progressive vision loss is one of the most consistent features of BBS. It usually begins with difficulty seeing in dim light (night blindness) during childhood, followed by gradual narrowing of peripheral vision. This is caused by a type of retinal degeneration similar to retinitis pigmentosa. The rate of progression varies — some people retain useful vision into their 30s or 40s, while others experience more rapid decline. Regular monitoring by a retinal specialist is essential.

Weight Management: Many people with BBS experience early-onset obesity that is resistant to typical diet and exercise approaches. This is not a matter of willpower — it results from disrupted signaling in the hypothalamus (the brain's appetite control center) caused by ciliary dysfunction. There is now an FDA-approved medication specifically for this (see Treatments below).

Kidney Health: Kidney abnormalities occur in a significant proportion of people with BBS, ranging from structural differences to progressive kidney disease. Regular kidney function monitoring through blood tests and imaging is important.

Extra Digits (Polydactyly): Some people with BBS are born with extra fingers or toes. This is often surgically corrected in infancy and typically does not cause ongoing issues.

Learning and Development: Some individuals with BBS experience learning differences or developmental delays. These vary widely — many people with BBS complete higher education and live independently, while others benefit from additional educational support.

Reproductive Health: Hypogonadism (underdeveloped reproductive organs) can affect puberty and fertility. An endocrinologist can help manage hormonal aspects of this.

Additional features that may occur include speech delays, dental crowding, heart abnormalities, liver fibrosis, diabetes, and hearing changes. Not everyone will experience all of these, and many can be effectively managed with appropriate medical care.

Current Treatments and Therapies

While there is not yet a single cure for all aspects of BBS, significant treatment advances have been made:

Approved Medication: Setmelanotide (Imcivree)

In June 2022, the FDA approved setmelanotide (brand name Imcivree, made by Rhythm Pharmaceuticals) specifically for chronic weight management in people with BBS aged 6 and older. In December 2024, this was expanded to children as young as 2 years old. Setmelanotide works by activating the MC4R pathway in the brain, which helps restore proper hunger signaling that is disrupted by ciliary dysfunction. Clinical trials showed meaningful reductions in hunger and body weight. Talk to your endocrinologist about whether this medication may be appropriate for you.

Emerging Therapies: GLP-1 Receptor Agonists

Research published in 2025 has shown that GLP-1 receptor agonists (a class of medications including semaglutide) may also be effective for managing obesity in BBS by bypassing the ciliary dysfunction pathway. Early case reports in pediatric BBS patients have shown promising results. This is an active area of investigation.

Gene Therapy Programs (For Vision)

Three gene therapy programs are currently in development targeting BBS-related retinal degeneration:

• AXV-101 (BBS1): Developed by Axovia Therapeutics and co-funded by A Race Against Blindness ($1.1M in January 2026). This AAV9-based gene therapy has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation. A Phase 1 first-in-human clinical trial (NCT07269665) is planned. Preclinical data showed dose-dependent halting of retinal degeneration in BBS1 mouse models.

• BBS10 Gene Therapy: A collaboration between the University of Iowa (Dr. Arlene Drack), InVision 2020, and MeiraGTx/Eli Lilly. In a world first, three pediatric patients received this AAV8-BBS10 gene therapy at St Helier Hospital in London (Aug 2025 – Jul 2026) through the UK MHRA Specials program — a compassionate access pathway, not a formal clinical trial. Patients travel to the University of Iowa for post-treatment evaluations. The program is evaluating safety and feasibility.

• BBS7 Gene Therapy: Developed at OHSU by Dr. Martha Neuringer using the world's first naturally occurring nonhuman primate model of BBS. Subretinal gene therapy slowed retinal degeneration and improved cone function in rhesus macaques.

Supportive Care

A multidisciplinary care team is the cornerstone of BBS management. Your team may include:

• Retinal specialist/ophthalmologist — monitoring vision and connecting you with low vision services
• Endocrinologist — managing weight, hormones, and metabolic health
• Nephrologist — monitoring kidney function
• Geneticist — confirming your specific mutation and advising on family planning
• Low vision specialist — teaching adaptive strategies and assistive technology
• Dietitian — supporting healthy nutrition approaches
• Psychologist or counselor — supporting emotional well-being

BBS Centers of Excellence

Several medical centers in the United States now offer specialized, multidisciplinary BBS care:

| Center | Location | Lead Clinician(s) | Focus |
|--------|----------|-------------------|-------|
| Marshfield Clinic | Marshfield, WI | Dr. Uzo Okorie | Multidisciplinary (30+ patients since 2014) |
| Mayo Clinic | Rochester, MN | Dr. Seema Kumar, Dr. Lisa Schimmenti | Endocrinology, Clinical Genomics |
| Penn Medicine / CHOP | Philadelphia, PA | Dr. Ted Drivas, Dr. Alana Strong | Ciliopathies, Genetics |
| Our Lady of the Lakes | Baton Rouge, LA | Dr. Katie Queen | Pediatric Obesity |
| OU Health Sciences Center | Tulsa, OK | Dr. Jesse Richards | Adult Obesity Medicine |
| University of Iowa | Iowa City, IA | Dr. Arlene Drack | Ophthalmology, Gene Therapy Research |
| Lurie Children's / Northwestern | Chicago, IL | Dr. Gal Finer | Pediatric Nephrology |

Internationally, the UK BBS Clinic (founded by Prof. Philip Beales) has been providing specialized BBS care since the early 2010s, and multidisciplinary centers exist in the Netherlands, Norway, Germany, and France.

What to Do Next

Taking these steps will help you build a strong foundation for managing BBS:

1. Get genetic testing if you haven't already. Knowing your exact gene mutation (e.g., BBS1, BBS10) is critical for understanding your prognosis, potential eligibility for gene therapy trials, and family planning decisions.

2. Establish care at a BBS Center of Excellence or assemble a multidisciplinary team. The Bardet-Biedl Syndrome Foundation maintains an updated list of clinics at bardetbiedl.org/clinical-practice.

3. Get a comprehensive baseline evaluation including a dilated eye exam with retinal imaging (OCT), kidney function tests, metabolic panel, and hearing assessment.

4. Connect with low vision services early. Don't wait until vision loss is advanced. Orientation and mobility training, assistive technology, and adaptive strategies can help you maintain independence.

5. Ask about setmelanotide if weight management is a concern. Your endocrinologist can determine if this FDA-approved therapy is appropriate for you.

6. Register with CRIBBS (Clinical Registry Investigating Bardet-Biedl Syndrome) at bbs-registry.org. This helps researchers understand BBS better and may connect you with future clinical trial opportunities.

7. Join the BBS community. Connect with the Bardet-Biedl Syndrome Foundation (bardetbiedl.org), attend their annual conference, and join their online support groups. Meeting others who understand your experience is invaluable.

Community Resources and Support Organizations

• Bardet-Biedl Syndrome Foundation (BBSF) — bardetbiedl.org — Annual conference, family support, research funding, Centers of Excellence program
• BBS UK — bbsuk.org.uk — UK-based support and information
• Foundation Fighting Blindness — fightingblindness.org — Largest private funder of retinal disease research, clinical trial information
• A Race Against Blindness — araceagainstblindness.org — Nonprofit funding sight-saving research for children, co-funder of AXV-101
• InVision 2020 — Funded BBS10 gene therapy research
• Rhythm Cares — rhythmtx.com — Patient support program for Imcivree (setmelanotide)
• National Federation of the Blind — nfb.org — Advocacy, resources, and community for people with vision loss
• American Foundation for the Blind — afb.org — Technology resources, career support
• VisionAware — visionaware.org — Practical daily living tips for vision loss

Clinical Trials You May Be Eligible For

Active clinical trials related to BBS (as of July 2026):

| Trial | Focus | Status | ID |
|-------|-------|--------|-----|
| AXV-101 Phase 1 | BBS1 retinal gene therapy | Not Yet Recruiting | NCT07269665 |
| MC4R Agonist Real-World Study | Setmelanotide in BBS | Recruiting | NCT07674290 |
| COBRA Cohort | BBS/Alström translational research | Recruiting | NCT04461444 |
| CRIBBS Registry | BBS natural history | Recruiting | NCT02329210 |

Visit clinicaltrials.gov and search "Bardet-Biedl Syndrome" to see the most current list.

You Are Not Alone

A BBS diagnosis is life-changing, but it does not define your future. People with BBS lead fulfilling lives — they work, build families, pursue education, and contribute to their communities. The research landscape is more promising than ever, with gene therapies advancing toward clinical trials and new medications already available. The BBS community is strong, welcoming, and ready to support you.

Take things one step at a time. Reach out to the organizations listed above. Attend a BBS conference if you can. And know that dedicated researchers, clinicians, and advocates around the world are working every day to improve life for people with BBS.

---

This guide was prepared by ClearSight Research (education.araceagainstblindness.org), a free educational resource of A Race Against Blindness, a 501(c)(3) nonprofit funding sight-saving research for children with inherited retinal diseases. Last updated July 2026.